Background and aims Several studies were conducted to explore the prognostic value of
platelet-to-lymphocyte ratio (PLR) in pancreatic cancer and have reported contradictory …

Lung cancer is responsible for the leading cause of cancer-related death worldwide, which
lacks effective therapies. In recent years, accumulating evidence on the understanding of the …

Methods Clinically annotated samples from 49 patients with advanced HCC treated with ICB
were analyzed for CD38 expression using immunohistochemistry (IHC), multiplex …

Our recent study demonstrated that the QKI-5 regulated miRNA, miR-196b-5p, and it
functions as an onco-microRNA in non-small cell lung cancer (NSCLC) by directly targeting …

CD38 is a transmembrane glycoprotein that is widely expressed in a variety of human
tissues and cells, especially those in the immune system. CD38 protein was previously …

Daratumumab (Darzalex, Janssen Biotech) is a clinically approved antibody targeting CD38
for the treatment of multiple myeloma. However, CD38 is also expressed by other cancer cell …

The immune environment is a determinant of whether patients with cancer can benefit from
immunotherapy. Immune checkpoint inhibitors (ICIs) have improved the prognosis of …

Current methods for diagnosis and treatment of small cell lung cancer (SCLC) have only a
modest efficacy. In this pilot study, we analyzed circulating tumor cells (CTCs) and cancer …

Background Processes and mechanisms responsible for systemic immune suppression in
early-stage cervical cancer remain substantially underinvestigated. In this work, we focused …

Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-associated mortality
in the world. However, with the associated low five-year survival and high recurrence rates …